After culling workforce, migraine biotech Zosano drops lead — and sole — program

It appears Zosano may not have much left in the tank.

In April, the migraine-focused biotech announced that it would cull about a third of its workforce — less than a month after the FDA refused to review the company’s resubmission for its migraine treatment patch known as M207....

Click to view original post